
Walgreens Boots (WBA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: May 2025Income Metrics
Revenue
39.0B
Gross Profit
6.5B
16.69%
Operating Income
13.0M
0.03%
Net Income
-196.0M
-0.50%
EPS (Diluted)
$-0.20
Balance Sheet Metrics
Total Assets
69.4B
Total Liabilities
62.1B
Shareholders Equity
7.3B
Debt to Equity
8.48
Cash Flow Metrics
Operating Cash Flow
696.0M
Free Cash Flow
336.0M
Revenue & Profitability Trend
Walgreens Boots Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 147.7B | 139.1B | 132.7B | 132.5B | 122.0B |
Cost of Goods Sold | 121.1B | 112.0B | 104.4B | 104.4B | 95.9B |
Gross Profit | 26.5B | 27.1B | 28.3B | 28.1B | 26.1B |
Gross Margin % | 18.0% | 19.5% | 21.3% | 21.2% | 21.4% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 28.1B | 34.2B | 27.3B | 24.6B | 25.4B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 28.1B | 34.2B | 27.3B | 24.6B | 25.4B |
Operating Income | -1.6B | -7.1B | 970.0M | 3.5B | 642.0M |
Operating Margin % | -1.1% | -5.1% | 0.7% | 2.6% | 0.5% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 482.0M | 580.0M | 400.0M | 905.0M | 613.0M |
Other Non-Operating Income | -12.1B | 2.3B | 3.4B | -581.0M | 418.0M |
Pre-tax Income | -14.2B | -5.4B | 4.0B | 2.0B | 446.0M |
Income Tax | 1.2B | -1.9B | -30.0M | 667.0M | 339.0M |
Effective Tax Rate % | 0.0% | 0.0% | -0.8% | 33.4% | 76.0% |
Net Income | -15.4B | -3.5B | 4.1B | 2.5B | 424.0M |
Net Margin % | -10.5% | -2.5% | 3.1% | 1.9% | 0.3% |
Key Metrics | |||||
EBITDA | 1.4B | -2.6B | 6.4B | 4.9B | 3.0B |
EPS (Basic) | $-10.01 | $-3.57 | $5.02 | $2.94 | $0.52 |
EPS (Diluted) | $-10.01 | $-3.57 | $5.01 | $2.93 | $0.52 |
Basic Shares Outstanding | 863100000 | 863200000 | 864400000 | 864800000 | 879400000 |
Diluted Shares Outstanding | 863100000 | 863200000 | 864400000 | 864800000 | 879400000 |
Income Statement Trend
Walgreens Boots Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.3B | 728.0M | 1.4B | 559.0M | 469.0M |
Short-term Investments | 1.8B | 11.0M | 1.1B | 634.0M | - |
Accounts Receivable | 5.9B | 5.4B | 5.0B | 5.7B | 4.1B |
Inventory | 8.3B | 8.3B | 8.4B | 8.2B | 7.9B |
Other Current Assets | 1.1B | 1.1B | 1.1B | 799.0M | 598.0M |
Total Current Assets | 18.3B | 15.5B | 16.9B | 15.8B | 18.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 20.3B | 21.7B | 21.3B | 21.9B | 21.5B |
Goodwill | 44.0B | 70.0B | 55.3B | 34.8B | 34.1B |
Intangible Assets | 13.0B | 13.6B | 10.7B | 9.9B | 10.1B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.8B | 2.6B | 1.7B | 2.0B | 5.6B |
Total Non-Current Assets | 62.7B | 81.1B | 73.2B | 65.5B | 69.1B |
Total Assets | 81.0B | 96.6B | 90.1B | 81.3B | 87.2B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 14.1B | 12.6B | 11.3B | 11.1B | 10.1B |
Short-term Debt | 3.9B | 3.3B | 3.3B | 3.6B | 5.6B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | -1.0M | - | - | -1.0M | 5.3B |
Total Current Liabilities | 27.0B | 24.5B | 22.6B | 22.1B | 27.1B |
Non-Current Liabilities | |||||
Long-term Debt | 29.0B | 30.3B | 32.1B | 29.8B | 34.0B |
Deferred Tax Liabilities | 1.2B | 1.3B | 1.4B | 1.8B | 1.4B |
Other Non-Current Liabilities | 5.7B | 5.8B | 3.0B | 3.4B | 3.2B |
Total Non-Current Liabilities | 41.9B | 43.6B | 37.1B | 35.1B | 39.0B |
Total Liabilities | 68.9B | 68.1B | 59.7B | 57.1B | 66.0B |
Equity | |||||
Common Stock | 12.0M | 12.0M | 12.0M | 12.0M | 12.0M |
Retained Earnings | 23.3B | 33.1B | 37.8B | 35.1B | 34.2B |
Treasury Stock | 20.7B | 20.7B | 20.7B | 20.6B | 20.6B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 12.2B | 28.5B | 30.4B | 24.1B | 21.1B |
Key Metrics | |||||
Total Debt | 32.9B | 33.5B | 35.5B | 33.4B | 39.6B |
Working Capital | -8.6B | -9.0B | -5.7B | -6.2B | -9.0B |
Balance Sheet Composition
Walgreens Boots Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -15.4B | -3.5B | 4.1B | 2.5B | 424.0M |
Depreciation & Amortization | 2.5B | 2.3B | 2.0B | 2.0B | 1.9B |
Stock-Based Compensation | 182.0M | 385.0M | 391.0M | 155.0M | 137.0M |
Working Capital Changes | 383.0M | 1.6B | 633.0M | -618.0M | -67.0M |
Operating Cash Flow | -11.7B | -1.8B | 4.2B | 4.0B | 2.8B |
Investing Activities | |||||
Capital Expenditures | -483.0M | -350.0M | -426.0M | -523.0M | -650.0M |
Acquisitions | -402.0M | -7.3B | -2.2B | 4.1B | -718.0M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 1.9B | -3.1B | -1.1B | 4.1B | -1.3B |
Financing Activities | |||||
Share Repurchases | -69.0M | -150.0M | -187.0M | -110.0M | -1.6B |
Dividends Paid | -1.3B | -1.7B | -1.7B | -1.6B | -1.7B |
Debt Issuance | 31.4B | 6.3B | 12.0B | 12.7B | 20.4B |
Debt Repayment | -30.5B | -9.0B | -8.4B | -15.3B | -21.4B |
Financing Cash Flow | -538.0M | -887.0M | -1.5B | -9.1B | -4.7B |
Free Cash Flow | -363.0M | 141.0M | 2.2B | 4.2B | 4.1B |
Net Change in Cash | -10.4B | -5.8B | 1.7B | -986.0M | -3.2B |
Cash Flow Trend
Walgreens Boots Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.10
Forward P/E
8.22
Price to Book
1.46
Price to Sales
0.07
PEG Ratio
-0.18
Profitability Ratios
Profit Margin
-4.07%
Operating Margin
0.74%
Return on Equity
-69.58%
Return on Assets
0.83%
Financial Health
Current Ratio
0.60
Debt to Equity
409.88
Beta
0.77
Per Share Data
EPS (TTM)
$-7.29
Book Value per Share
$8.30
Revenue per Share
$178.88
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
wba | 10.5B | 27.10 | 1.46 | -69.58% | -4.07% | 409.88 |
High Tide | 248.5M | -61.20 | 1.77 | -6.69% | -1.76% | 44.69 |
PetMed Express | 62.6M | 303.00 | 0.65 | 0.36% | 0.15% | 1.15 |
Wellgistics Health | 56.8M | -5.47 | 10.27 | -2,124.65% | -135.22% | 571.67 |
Scienture Holdings | 19.5M | 2.37 | 0.25 | -54.26% | 4.39% | 5.30 |
Hong Kong Pharma | 11.5M | 6.26 | 2.31 | -0.59% | -0.13% | 47.60 |
Financial data is updated regularly. All figures are in the company's reporting currency.